Janus Henderson Group PLC Bluebird Bio, Inc. Transaction History

Janus Henderson Group PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.02 - $4.05 $9 - $12	3 Added 0.01%	40,598 $123,000
Q2 2023 Aug 14, 2023	SELL	$2.79 - $5.03 $119 - $216	-43 Reduced 0.11%	40,595 $133,000
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $58,686 - $153,631	18,690 Added 85.16%	40,638 $129,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $126,639 - $186,338	21,948 New	21,948 $151,000
Q2 2022 Aug 15, 2022	SELL	$2.94 - $5.23 $40,125 - $71,379	-13,648 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $69 - $180	17 Added 0.12%	13,648 $66,000
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $122,133 - $222,321	13,631 New	13,631 $136,000
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $448,646 - $760,481	-16,543 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $331,237 - $804,037	-12,662 Reduced 43.36%	16,543 $760,000
Q4 2019 Feb 18, 2020	BUY	$46.96 - $61.67 $1.37 Million - $1.8 Million	29,205 New	29,205 $2.56 Million
Q3 2018 Nov 09, 2018	SELL	$88.86 - $117.49 $195,492 - $258,478	-2,200 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$99.64 - $127.59 $4.76 Million - $6.1 Million	-47,800 Reduced 95.6%	2,200 $345,000
Q2 2017 Aug 17, 2017	BUY	N/A	50,000	50,000 $5.25 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.